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S133.e2 Ekwueme et alBackground: Cutaneous melanoma is the most deadly form of skin cancer with more than 8000 deaths per
year in the United States. The health burden and economic costs associated with melanoma mortality by
race/ethnicity have not been appropriately addressed.Objective: We sought to quantify the health burden and economic costs associated with melanoma
mortality among racial/ethnic groups in the United States.Methods: We used 2000 to 2006 national mortality data and US life tables to estimate the number
of deaths, and years of potential life lost (YPLL). Further, we estimated the economic costs of
melanoma mortality in terms of productivity losses. All the estimates were stratified by race/ethnicity
and sex.Results: From 2000 to 2006, we estimated an increase of 13,349 (8.7%) YPLL because of melanoma
mortality compared with a 2.8% increase among all malignant cancers across all race/ethnicity. On average,
an individual in the United States loses 20.4 years of potential life during their lifetime as a result of
melanoma mortality compared with 16.6 years for all malignant cancers. The estimated annual productivity
loss attributed to melanoma mortality was $3.5 billion. Our estimates suggest that an individual who died
from melanoma in 2000 through 2006 would lose an average of $413,370 in forgone lifetime earnings. YPLL
rates and total productivity losses are much higher among non-Hispanic whites as compared with
non-Hispanic blacks and Hispanics.Limitations: The estimated economic costs did not include treatment, morbidity, and intangible costs.Conclusions: We estimated substantial YPLL and productivity losses as a result of melanoma mortality
during an individual’s lifetime. By examining the burden by race/ethnicity, this study provides useful
information to assist policy-makers in making informed resource allocation decisions regarding
cutaneous melanoma mortality. ( J Am Acad Dermatol 2011;65:S113.e1-12.)
Keywords: cancer; economic cost; melanoma; mortality; productivity loss; race/ethnicity; years of potential
life lost.Cutaneous melanoma (hereafter called mela-
noma) is the third most common form of skin cancer
after basal and squamous cell carcinomas. It is a
deadly form of skin cancer with more than 8000
deaths per year.1 The average lifetime risk of devel-
oping melanoma in the United States has increased
from 1 in 1500 in 1935 to 1 in 30 in 2009.2,3 As athe Division of Cancer Prevention and Control, National
enter for Chronic Disease Prevention and Health Promotion,
enters for Disease Control and Prevention, Atlantaa; Depart-
ent of Health Promotion and Behavioral Sciences, University
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terans Affairs Medical Centerd.
ication of this supplement to the JAAD was supported by the
ivision of Cancer Prevention and Control, Centers for Disease
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licts of interest: None declared.result, the health burden measured by mortality
associated with melanoma has increased over time
and is reported to disproportionately affect non-
Hispanic whites and other racial/ethnic groups with
fair-skinned complexion.4,5
Quantifying health status in human populations is
often measured by mortality; however, mortalityThe opinions or views expressed in this supplement are those of
the authors and do not necessarily reflect the opinions,
recommendations, or official position of the journal editors or
the Centers for Disease Control and Prevention.
Please see Appendix 1 for a glossary of technical terms used in this
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Ekwueme et al S133.e3does not fully address the issue of premature deaths,
particularly among younger populations.6,7 An alter-
native measure to use is years of potential life lost
(YPLL), which provides a more accurate measure of
mortality for the young and the elderly population.7,8
The burden of melanoma disease measured by using
YPLL by race/ethnicity has not been satisfactorilyCAPSULE SUMMARY
d An individual who died from melanoma
in the past 7 years (ie, 2000-2006) would
lose an average of $413,370 in forgone
lifetime earnings, whereas for all
malignant cancers an individual would
lose $309,879.
d On average, women lose 21.4 years of
potential life during their lifetime
because of melanoma compared with
19.0 years for men.
d Women have higher premature mortality
associated with melanoma than men.
d Non-Hispanic whites have a higher
health burden and economic cost
associated with melanoma mortality.
d These findings underscore the
importance of prevention, early
detection, and effective treatment.
d The results presented in this article
should be viewed as one of the best
available estimates to quantify the
burden of melanoma mortality by race/
ethnicity compared with 4 major cancers
and all malignant cancers.addressed.
The economic costs asso-
ciated with melanoma have
been estimated to be substan-
tial. Past studieshave reported
the costs of melanoma using
various economic methods.9-
11 For instance, Bickers et al9
(2006) and Bradley et al10
(2008) used thehumancapital
approach (HCA) to estimate
the cost of lost productivity
caused bymelanoma to range
from $2.9 billion in 2004 dol-
lars to $3.3 billion in 2010
dollars. The HCA values labor
and household productivity
that an individual contributes
to society.12 Alternatively,
Yabroff et al11 (2008) used
thewillingness-to-paymethod
to estimate the value of life lost
to society as a result of mela-
noma to be $15.1 billion in
2000 dollars with a projected
increase to $21.6 billion in
2020. The willingness-to-pay
method measures the amount
of money or resources an in-
dividual would pay to reduce
the probability of illness or
dying from melanoma.13 This method is more com-
prehensive as it includes costs of lost productivity
and intangible costs such as pain and suffering
caused by melanoma. These economic studies
have provided strong evidence of the substantial
costs attributed to melanoma at the societal level.
However, information on economic costs associated
with melanoma among racial/ethnic groups is not
currently available in the literature.
The purpose of this study is 2-fold: first, we
quantified the health burden associated with mela-
noma mortality measured by YPLL. Second, we
estimated the economic costs associated with mela-
noma mortality measured by the value of lifetime
productivity losses. We compared the findings with
estimates from 4 major cancers (ie, female breast
[breast], prostate, colorectal, and lung/bronchus[lung]) and all malignant cancers. All the estimates
were stratified by race/ethnicity.METHODS
We used 3 broad measures of disease burden to
quantify the magnitude of melanoma and compared
its impact relative to the 4 major cancers listed aboveand against all malignant
cancers. These burden mea-
sures included mortality,
YPLL, and the value of pro-
ductivity losses from mortal-
ity. Mortality associated with
melanoma, the 4 major can-
cers, and all malignant can-
cers were used in conjunction
with data from the US life
tables, and from the literature
to estimate YPLL and the
value of productivity loss
caused by mortality. We con-
structed a model of disease
burden to estimate foregone
lifetime productivity lost in
termsof incidence-basedcosts
as opposed to prevalence-
based costs.14-16 Productivity
losses were measured using
the HCA.17-19 This approach
values labor productivity
acquired through an invest-
ment in education, on-the-job
training, and work experi-
ence,20 and the value of
nonwage labor productivity
performed in the household.Data sources and extraction
We used the Surveillance, Epidemiology, and End
Results (SEER)*Stat software (Version 6.5.2) to extract
cancer mortality and associated population data that
cover 100% of US deaths.21 The mortality data from
SEER*Stat for melanoma; breast, prostate, colorectal,
and lung cancer; and for all malignant cancers from
2000 to 2006 were obtained from the Centers for
Disease Control and Prevention National Vital
Statistics Surveillance System.22 Mortality from mel-
anoma and the 4 major cancers were coded as the
underlying cause of death at primary cancer site
using the International Statistical Classification of
Diseases, 10th Revision with C43 for melanoma; C50
for breast, C61 for prostate, C18 to C21 for colorectal,
and C33 to C34 for lung cancers; and C00 to C97 for
all malignant cancers.23
Abbreviations used:
HCA: human capital approach
PVFLE: present value of future lifetime earnings
SEER: Surveillance, Epidemiology, and
End Results
YPLL: years of potential life lost
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SEER*Stat were used for calculating crude rates
and age-adjusted rates were obtained from the
2000 US Census.24 All rates are expressed per
100,000 population. We extracted data on individ-
uals aged 15 years or older, by 5-year age groups
and sex. We excluded individuals aged 0 to 14 years
because no deaths frommelanomawere reported in
this age group. We constructed 4 mutually exclusive
racial/ethnic categories: non-Hispanic white, non-
Hispanic black, non-Hispanic other (ie, Asian/
Pacific Islanders and American Indian/Alaska
Natives), and Hispanic.
Estimation of YPLL, average YPLL, YPLL rates,
and age-adjusted rates
We used the life expectancy method to calculate
YPLL7,8,16 rather than using an arbitrary age cutoff of
70 or 75 years that has been used in previous
studies.25-27 This method is defined as the expected
YPLL because of a particular disease, such as mela-
noma, during an individual’s lifetime.8 We believed
that this approach is appropriate in particular to
cancerwhere themajority of deaths are highly skewed
toward the elderly population. Based on this method,
we calculated YPLL in each 5-year age group by
the corresponding remaining life expectancy ob-
tained from the 2000 to 2006 US life tables.28-35
The estimated number of YPLL in each 5-year
age group was summed to obtain the total YPLL
for melanoma, 4 major cancers, and all malignant
cancers in individuals aged 15 years or older. The
estimation was stratified by race/ethnicity and sex.
Because current life tables do not report life expec-
tancy for Asian/Pacific Islanders and American
Indian/Alaska Natives, we used the life tables data
on all races as a proxy for non-Hispanic other.28-35 To
compare YPLL across racial/ethnic groups, we esti-
mated crude and age-adjusted rates (YPLL/100,000
population). Age-adjusted rates were calculated by
the direct method, using the 2000 US standard
population by 5-year groups.36 Further, we examined
mortality from melanoma and other major cancers in
non-Hispanic whites compared with each racial/
ethnic group by calculating rates and rate ratios. We
used the YPLL rates in non-Hispanic whites as thereferent. In addition to the estimation of YPLL, we
also calculated average YPLL, crude rates, and rate
ratios by race/ethnicity. We also calculated absolute
change in mortality and YPLL for 2000 and 2006,
percent change, and percent contribution of each of
the 4 major cancer sites compared with melanoma.
Estimation of mortality costs
Productivity costs caused by premature mortality
from melanoma, 4 other major cancers, and all
malignant cancers were estimated using the number
of deaths in 2006 multiplied by the present value of
future lifetime earnings (PVFLE) stratified by age,
sex, and race/ethnicity. The data on the PVFLE were
obtained from a published study.37 The PVFLE esti-
mate took into account factors such as life expec-
tancy, labor force participation rate, future growth
rate in productivity, and imputed value of house-
keeping services (eg, cooking, cleaning, childcare).
We applied a 3% discount rate in estimating the
PVFLE and examined how our results changed when
we applied a 0% and a 5% discount rate. The
discount rate was used to convert future earnings
for these people who died to present value.13 In
addition to estimating the total PVFLE lost caused by
melanoma mortality, we also estimated the total
PVFLE from 4 major cancers and all malignant
cancers. We also estimated the cost of premature
death on an individual level. All costs presented in
this study were standardized to 2006 US dollars.
RESULTS
Years of potential life lost
In 2000 and 2006, a total of 7419 and 8437
Americans died from melanoma, respectively,
which represented an increase of 1018 (13.7%)
deaths. These deaths accounted for an estimated
152,912 to 166,261 YPLL, representing an increase
of 13,349 (8.7%) in premature mortality from 2000
to 2006 compared with 2.8% premature mortality
for all malignant cancers (Table I). On average, an
individual in the United States could lose 20.4 years
of potential life during his or her lifetime because of
melanoma mortality, which is greater than 16.2
years for the 4 major cancers (ie, breast, prostate,
colorectal, and lung), and 16.6 years for all malig-
nant cancers.
For men, we estimated an increase of 883 deaths
caused by melanoma and an estimated increase of
12,432 YPLL. This estimate represents an 18.9%
increase in melanoma contribution to mortality
among the 4 major cancers. These 4 major cancers
contributed to a 25% to 58% decrease in cancer
mortality (Table I). For women, we estimated an
increase of 135 melanoma deaths and an estimated
Table I. Contribution of individual cancer sites to increase or decrease in deaths and years of potential life lost by sex, 2000 to 2006*
Mortality YPLL
2000-2006
Cancer sites by sex
Total
2000
Total
2006
Absolute
change
%
Changey
%
Contributionz
Total
2000
Total
2006
Absolute
change
%
Changey
%
Contributionz
Per
deathsx
Crude
ratek
Age-
adjusted
ratek
Male
All malignant
cancers
285,220 289,311 4091 1.43 4,288,300 4,474,493 186,193 4.34 15.4 3962.6 4234.2
Melanoma 4591 5474 883 19.23 18.9 87,739 100,171 12,432 14.17 338.1 19.0 84.6 87.6
Prostate 31,078 28,371 2707 8.71 57.9 297,876 280,960 16,916 5.68 460.1 9.9 262.3 310.2
Colorectal 28,481 26,800 1681 5.90 36.0 413,314 410,030 3284 0.78 89.3 15.1 373.4 400.5
Lung and bronchus 90,407 89,240 1167 1.29 25.0 1,373,535 1,377,627 4092 0.30 111.3 15.5 1245.0 1328.8
Total{ 154,557 149,885 4672 3.33 100.0 2,172,465 2,168,788 3677 7.99 100.0
Female
All malignant
cancers
266,334 269,209 2875 1.08 4,590,923 4,672,555 81,633 1.78 17.5 3957.6 3737.8
Melanoma 2828 2963 135 4.77 15.5 61,131 61,656 525 0.86 1.6 21.4 51.9 50.3
Female breast 41,872 40,819 1053 2.51 121.2 838,987 824,370 14,617 1.74 44.7 20.3 711.8 681.8
Colorectal 28,949 26,395 2554 8.82 293.9 418,186 399,100 19,086 4.56 58.4 14.9 347.7 322.7
Lung and bronchus 65,014 69,355 4341 6.68 499.5 1,122,180 1,188,059 65,879 5.87 201.5 17.4 993.4 934.9
Total{ 138,663 139,532 869 0.11 100.0 2,440,484 2,473,185 32,701 0.42 100.0
Male and female
All malignant
cancers
551,554 558,520 6966 1.26 9,012,445 9,261,924 249,478 2.77 16.6 4015.9 3993.1
Melanoma 7419 8437 1018 13.72 2367.4 152,912 166,261 13,349 8.73 30.8 20.4 69.7 69.3
Colorectal 57,430 53,195 4235 7.37 9848.8 846,087 821,322 24,766 2.93 57.1 15.3 366.3 364.3
Lung and bronchus 155,421 158,595 3174 2.04 7381.4 2,561,079 2,615,885 54,807 2.14 126.3 16.7 1141.2 1135.5
Total{ 220,270 220,227 43 8.39 100.0 3,560,078 3,603,467 43,389 7.94 100.0
Grand total# 293,320 289,417 3803 1.30 54.6 4,774,536 4,692,358 82,178 1.72 32.9 16.3 2063.3 2052.5
YPLL, Years of potential life lost.
*Data presented are for all races/ethnicities age 151 (5-year age group).
yCalculated by dividing the absolute change for each cancer site by the number of deaths or YPLL in 2000.
zThe percent contribution is based on each cancer site’s contribution in increasing or decreasing portion of the number of cancer deaths or YPLL divided by the sum of absolute change in mortality
or premature deaths.
xYPLL per death was calculated by dividing the estimated number of YPLL in each cancer site by the number of deaths that occurred prematurely.
kRates and age-adjusted rates are per 100,000 persons. Age-adjusted rates were calculated by the direct method using the 2000 US standard population in 5-year groups (ie, ages 15-19 years, 20-24
years, . . ., 851 years; see Surveillance Epidemiology, and End Results Program 2007).21
{Total excludes data from all malignant cancers.
#Grand total is the combination of the following major cancers: melanoma, breast, colorectal, prostate, and lung and bronchus. For the four major cancers (ie, breast, colorectal, prostate, and lung
and bronchus) the estimated YPLL per death was 16.2.
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Fig 1. Proportion of years of potential life lost (YPLL)
because of melanoma relative to years of potential life lost
because of all malignant cancers, by age at death and
sexeUnited States, 2000 to 2006.
J AM ACAD DERMATOL
NOVEMBER 2011
S133.e6 Ekwueme et alincrease of 525 YPLL. For the 7-year period (2000-
2006), we estimated 21.4 YPLL per death caused by
melanoma compared with YPLL per death ranging
from 14.9 for colorectal cancer to 20.3 for breast
cancer. In both men and women, the estimated
overall age-adjusted YPLL rate for melanoma was
69.3 per 100,000, 87.6 per 100,000 for men, and 50.3
per 100,000 for women.
In general, men had a 6.5 times (883/135) higher
mortality frommelanoma than women. However, on
an individual basis, the impact of premature mortal-
ity measured by YPLL per death was higher in
women (21.4) than in men (19.0). This implies that
although men may have higher mortality burden
associated with melanoma, the disease affects
women at a younger age. This point is clearly
illustrated in Fig 1, which demonstrates that the
proportion of YPLL as a result of melanoma relative
to YPLL from all malignant cancers varied by age and
sex. Overall, men had the largest relative contribu-
tion to YPLL starting from age 25 years through the
remainder of their lives, with the greatest contribu-
tion at age 30 to 34 years. On the other hand, women
have relative contributions to YPLL starting at age 20
years through the remainder of their lives, with the
greatest contribution at age 25 to 29 years.
We estimated 1.1 million (95.5%) YPLL as a result
of melanoma in non-Hispanic whites, 25,337 (2.3%)
in Hispanics, and 14,861 (1.3%) in non-Hispanic
blacks (Table II). For non-Hispanic whites, the
estimated YPLL rate was 87.7 per 100,000. Using
non-Hispanic whites as the reference group the
estimated YPLL rate ratio ranged from 0.1 to 0.2 for
non-Hispanic blacks and Hispanics, respectively.
Melanoma accounted for 1.8% of the estimated
63.6 million YPLL among all malignant cancers.
Among the 4 major cancers and melanoma, we
estimated a total of 32.8 million YPLL from 2000 to
2006; of which, melanoma accounted for 3.4%.
Prostate accounted for 6.1%, colorectal and breast
cancers each accounted for 17.6%, and lung ac-
counted for 55.2% (Table II). In the past 7 years,
these 4 major cancers and melanoma accounted for
an average of 52.6% of mortality and 51.6% of YPLL
that have occurred among all malignant cancers
(data not shown). The relative contributions of
each of these 4 cancer sites to mortality and YPLL
are presented in Appendix 2.
Mortality-related productivity costs
In 2006, the estimated lifetime cost associated
with melanoma mortality discounted at 3% rate was
$3.5 billion (discount rate range from 5%-0%: $2.9-
$5.1 billion) (Table III). At an individual level, we
estimated this cost to be $413,370 (discount raterange from 5%-0%: $338,469-$602,265) per death.
Deaths among men accounted for $2.4 billion (dis-
count rate range from 5%-0%: $2.0-$3.5 billion) of
lost productivity (or 67.1% of the total), with an
average cost per death of $441,903 (discount rate
range from 5%-0%: $365,268-$630,438). Deaths
among women accounted for $1.2 billion (discount
rate range from 5%-0%: $0.9-$1.8 billion) of lost
productivity (or 32.9% of the total), with an average
cost per death of $401,046 (discount rate range from
5%-0%: $324,925-$598,214).
In the order of lowest to highest, the estimated
racial/ethnic-specific lifetime mortality cost associ-
ated with melanoma was $28.6 million (discount rate
range from 5%-0%: $23.1-$43.3 million) with an
average cost per death of $461,795 (discount rate
range from 5%-0%: $372,372-$697,735) for non-
Hispanic other; $50.9 million (discount rate range
from 5%-0%: $41.5-$75.1 million) with average cost
per death of $413,913 (discount rate range from
5%-0%: $337,063-$610,804) for non-Hispanic blacks;
$110.8 million (discount rate range from 5%-0%:
$88.4-$170.5 million) with average cost per death of
$545,795 (discount rate range from 5%-0%: $435,604-
$840,317) for Hispanics; and $3.3 billion (discount
rate range from 5%-0%: $2.7-$4.8 billion) with aver-
age cost per death of $409,814 (discount rate range
from 5%-0%: $335,910-$595,654) for non-Hispanic
whites.
DISCUSSION
In this study, we quantified the burden of mela-
noma mortality measured by YPLL and the associ-
ated economic costs by race/ethnicity from 2000 to
2006. The results were summarized in two broad
measures of cancer disease burden. First, for men
and women, we estimated an increase in YPLL of
Table II. Years of potential life lost, rate, and rate ratio by sex, cancer site, and race/ethnicityeUnited States,
2000 to 2006
Cancer site by race/
ethnicity
Male Female Total*
No. of
YPLL
YPLL rate/
100,000
Rate
ratio
No. of
YPLL
YPLL rate/
100,000
Rate
ratio
No. of
YPLL
YPLL rate/
100,000
Rate
ratio
Melanoma of skin
Non-Hispanic white 638,306 110.1 1.00 405,365 63.9 1.00 1,072,150 87.7 1.00
Non-Hispanic black 6722 9.6 0.09 7945 8.8 0.14 14,861 9.3 0.11
Non-Hispanic othery 3727 11.3 0.10 3906 9.8 0.15 7714 10.6 0.12
Hispanic 13,514 19.9 0.18 11,228 15.1 0.24 25,337 17.7 0.20
Prostate
Non-Hispanic white 1,526,865 279.3 1.00 e e e e e e
Non-Hispanic black 360,060 701.8 2.51 e e e e e e
Non-Hispanic othery 29,550 132.0 0.47 e e e e e e
Hispanic 90,587 235.9 0.84 e e e e e e
Female breast
Non-Hispanic white e e e 4,430,911 668.7 1.00 e e e
Non-Hispanic black e e e 890,571 947.5 1.42 e e e
Non-Hispanic othery e e e 157,940 390.6 0.58 e e e
Hispanic e e e 314,905 433.1 0.65 e e e
Colorectal
Non-Hispanic white 2,276,469 393.2 1.00 2,194,289 311.8 1.00 4,547,584 355.4 1.00
Non-Hispanic black 359,571 551.7 1.40 413,951 466.3 1.50 787,242 510.8 1.44
Non-Hispanic othery 80,392 264.8 0.67 81,514 221.6 0.71 164,122 244.4 0.69
Hispanic 148,854 274.5 0.70 141,987 475.9 1.53 297,489 249.6 0.70
Lung and bronchus
Non-Hispanic white 8,009,140 1363.1 1.00 6,982,839 1010.9 1.00 15,299,351 1191.8 1.00
Non-Hispanic black 1,100,515 1683.1 1.23 817,253 921.2 0.91 1,993,514 1288.4 1.08
Non-Hispanic othery 196,756 682.0 0.50 156,075 435.4 0.43 361,363 558.3 0.47
Hispanic 275,255 269.6 0.20 176,761 288.6 0.29 471,798 424.6 0.36
All malignant cancers
Non-Hispanic white 24,633,682 4243.1 1.00 25,807,186 3786.3 1.00 51,129,883 4022.9 1.00
Non-Hispanic black 3,542,571 5417.0 1.28 3,992,467 4408.8 1.16 7,675,704 4887.4 1.21
Non-Hispanic othery 791,498 2600.1 0.61 886,985 2357.4 0.62 1,695,035 2486.5 0.62
Hispanic 1,481,043 2652.0 0.63 1,610,858 2371.1 0.63 3,141,607 2518.3 0.63
YPLL, Years of potential life lost.
Data presented are for all age groups starting from age 151 (5-year age group).
*Total includes male and female.
yIncludes Asian/Pacific Islanders and American Indian/Alaska natives.
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Ekwueme et al S133.e713,349 or 8.7% between 2000 to 2006 as a result of
melanoma compared with a 2.8% increase in all
malignant cancers. On the other hand, there was a
decrease in YPLL of 2.0% among the 4 major cancers
confirming reports that melanoma mortality has
increased in recent years compared with other can-
cer sites.3,38,39 In general, the increase in melanoma
mortality and YPLL is substantially higher in men
than in women. However, on an individual basis and
in all race/ethnicity, YPLL per melanoma death is
higher among women, which implies that this cancer
affects women at a younger age than men. This
finding is consistent with other published studies that
have reported primarily on melanoma in adolescent
and young adults.40,41 The observed difference in
premature deaths caused by melanoma in youngwomen and menmay be a result of the increased use
of indoor tanning particularly by white females aged
16 to 49 years.42-44 A recent study reported that
individuals who used indoor tanning before age 35
years have a 75% increased risk of developing
melanoma45 and women are more likely to use
indoor tanning than men.46
Second, we estimated the annual cost associated
with melanoma mortality to be $3.5 billion. Our
estimates suggest that an individual who died from
melanoma in 2000 through 2006 would lose an
average of $413,370 in forgone lifetime earnings.
On average, this estimate is 1.6 times higher than the
estimates from the 4 major cancers. For all malignant
cancers, the productivity loss per death was
$309,879, which is 1.3 times lower than the estimate
Table III. Estimated present value of future lifetime lost productivity by sex, cancer site, and race/ethnicityeUnited States, 2006
Male Female Total
Cancer site by
race/ethnicity
Discounted
total cost, $ 3 106
3% (5%-0%)
Discounted total
cost per death
3% (5%-0%)
Discounted total
cost, $ 3 106
3% (5%-0%)
Discounted total
cost per death
3% (5%-0%)
Discounted total
cost, $ 3 106
3% (5%-0%)
Discounted total
cost per death
3% (5%-0%)
Melanoma of skin
All race/ethnicity 2419.0 (1999.5-3451.0) 441,903 (365,268-630438) 1188.3 (962.8-1772.5) 401,046 (324,925-598,214) 3487.6 (2855.7-5081.3) 413,370 (338,469-602,265)
Non-Hispanic white 2306.1 (1908.1-3282.4) 437,751 (362,212-623,076) 1105.3 (896.4-1644.6) 398,156 (322,921-592,432) 3296.5 (2702.1-4791.4) 409,814 (335,910-595,654)
Non-Hispanic black 30.6 (25.0-44.8) 471,292 (385,351-689,398) 21.6 (17.5-32.1) 372,262 (302,134-553,169) 50.9 (41.5-75.1) 413,913 (337,063-610,804)
Non-Hispanic other* 13.8 (11.3-20.2) 461,389 (377,042-674,340) 14.9 (11.9-23.3) 466,896 (371,739-727,428) 28.6 (23.1-43.3) 461,795 (372,372-697,735)
Hispanic 68.2 (54.8-103.3) 625,822 (502,686-948,158) 46.0 (36.5-71.9) 489,165 (387,961-764,977) 110.8 (88.4-170.6) 545,795 (435,604-840,317)
Prostate
All race/ethnicity 4753.7 (4151.7-6026.0) 167,556 (146,335-212,401) e e e e
Non-Hispanic white 3462.2 (3031.3-4365.8) 158,569 (138,832-199,953) e e e e
Non-Hispanic black 943.2 (817.1-1216.0) 202,876 (175,767-261,559) e e e e
Non-Hispanic other* 77.5 (67.8-97.7) 167,691 (146,764-211,457) e e e e
Hispanic 262.8 (228.4-336.5) 191,410 (166,335-245,063) e e e e
Female breast
All race/ethnicity e e 15,490.5 (12,704.8-22,427.5) 379,491 (311,248-549,438) e e
Non-Hispanic white e e 11,157.3 (9202.6-15,958.1) 347,439 (286,571-496,935) e e
Non-Hispanic black e e 2766.4 (2237.6-4123.4) 491,281 (397,372-732,261) e e
Non-Hispanic other* e e 481.2 (390.5-711.7) 499,649 (405,528-739,032) e e
Hispanic e e 1064.9 (857.0-1605.1) 518,462 (417,215-781,445) e e
Colorectal
All race/ethnicity 8753.6 (7389.9-11,928.6) 326,626 (275,743-445,098) 6927.4 (5780.5-9687.0) 262,451 (219,000-367,003) 15,345.1 (12,866.2-21,227.1) 288,468 (241,869-399,043)
Non-Hispanic white 6489.3 (5496.4-8782.7) 305,811 (259,021-413,886) 5090.4 (4270.7-7033.5) 242,541 (203,485-335,122) 11,328.2 (9537.8-15,530.2) 268,390 (225,972-367,944)
Non-Hispanic black 1379.7 (1155.4-1909.9) 406,508 (340,431-562,743) 1130.6 (932.5-1619.2) 333,914 (275,388-478,199) 2456.5 (2040.5-3463.1) 362,322 (300,955-510,776)
Non-Hispanic other* 498.8 (412.4-711.3) 362,472 (299,724-516,951) 236.0 (193.2-344.5) 344,552 (282,082-502,877) 498.8 (412.4-711.3) 362,472 (299,724-516,951)
Hispanic 588.0 (489.9-824.7) 408,925 (340,654-573,530) 462.0 (377.3-677.9) 352,412 (287,769-517,105) 1029.5 (848.8-1478.0) 374,514 (308,760-537,641)
Lung and bronchus
All race/ethnicity 27,310.2 (23,295.0-36,347.6) 306,031 (261,037-407,301) 19,367.8 (16,229.8-26,736.2) 279,257 (234,011-385,497) 45,735.9 (38,636.9-62,097.0) 288,381 (243,620-391,545)
Non-Hispanic white 21,898.1 (18,711.2-29,037.8) 293,336 (250,645-388,976) 16,124.5 (13,540.8-22,152.9) 270,091 (226,814-371,071) 37,300.8 (31,570.7-50,436.0) 277,635 (234,985-375,402)
Non-Hispanic black 3814.0 (3227.2-5160.5) 391,900 (331,612-530,265) 2306.7 (1911.6-3260.5) 348,543 (288,849-492,665) 5958.6 (4987.8-8247.5 364,438 (305,067-504,435)
Non-Hispanic other* 662.0 (561.3-892.4) 340,017 (288,305-458,342) 427.7 (354.9-604.1) 317,769 (263,644-448,794) 1065.4 (893.4-1470.9) 323,549 (271,299-446,672)
Hispanic 882.1 (749.2-1185.1) 321,242 (272,841-431,585) 487.0 (404.1-688.4) 302,891 (251,329-428,110) 1337.6 (1122.8-1842.8) 307,204 (257,879-423,250)
All malignant cancers
All race/ethnicity 94,258.7 (79,460.3-129,101.7) 325,804 (274,653-446,239) 81,518.1 (67,524.8-115,794.4) 302,806 (250,827-430,128) 173,073.5 (144,555.6-241,634.1) 309,879 (258,819-432,633)
Non-Hispanic white 72,427.7 (61,284.2-98,378.4) 306,972 (259,743-416,960) 62,179.4 (51,756.7-87,361.2) 283,621 (236,080-398,484) 132,489.5 (111,124.4-183,236.4) 291,073 (244,135-402,562)
Non-Hispanic black 13,052.8 (10,925.4-18,133.4) 406,187 (339,984-564,288) 11,486.1 (9398.9-16,739.1) 381,229 (311,954-555,582) 24,175.3 (20,000.7-34,420.3) 388,271 (321,224-552,812)
Non-Hispanic other* 2761.5 (2297.0-3894.6) 393,484 (327,296-554,947) 2606.3 (2126.0-3829.9) 379,591 (309,648-557,806) 5302.2 (4366.9-7635.1) 381,893 (314,525-549,919)
Hispanic 5831.7 (4797.7-8442.1) 425,642 (350,174-616,170) 45,144.4 (4158.5-7721.0) 406,739 (328,785-610,450) 10,827.6 (8830.3-15,954.7) 410,931 (335,130-605,515)
Data presented are for all age groups starting from age 151 (5-year age group).
*Includes Asian/Pacific Islanders and American Indian/Alaska natives.
J
A
M
A
C
A
D
D
E
R
M
A
T
O
L
N
O
V
E
M
B
E
R
20
11
S
1
3
3
.e
8
E
kw
u
em
e
et
a
l
J AM ACAD DERMATOL
VOLUME 65, NUMBER 5
Ekwueme et al S133.e9from melanoma. These findings provided consistent
evidence that the economic burden of melanoma
disease is substantial9-11 and represents a serious
public health concern. Further, a recent systematic
review study presented a comparative melanoma
disease burden between the United States and other
countries.47 The study showed that in both YPLL and
productivity loss, the estimates were relatively higher
in the United States compared with other industrial-
ized countries.
Although this study demonstrates the substantial
costs of melanoma to each racial/ethnic group, with
non-Hispanic whites accounting for 95.1% of the
estimated total melanoma costs and Hispanics ac-
counting for 2.3%, it also highlights the potential
costs that could be saved if prevention programs
were designed to reduce the burden of melanoma
disease among these racial/ethnic groups. In the
past decade, prevention programs have been initi-
ated to reduce the burden of melanoma. Such
prevention programs have focused on reducing
exposure to ultraviolet radiation by increasing
knowledge and awareness through educational
programs, media campaigns, and by implementing
policy initiatives that encourage sun-safety prac-
tices.48 According to the US Preventive Services
Task Force, currently there is insufficient evidence
to recommend for or against regular skin cancer
screening including self-examination for early de-
tection of melanoma in the adult general popula-
tion.49 However, the Task Force on Community
Preventive Services found sufficient evidence to
recommend intervention programs that promote
and improve awareness of melanoma and other
skin cancers in primary schools and recreational or
tourism settings.48 These and similar efforts from
public and private health agencies and institutions
may be contributing to improving the awareness of
skin cancer diseases. However, these efforts may
not be enough. For example, in 1935 the average
lifetime risk of an American developing melanoma
was 1 in 1500 and in 2009, this probability has
increased to 1 in 30.2,3
The increasing risk of melanoma underscores
the importance of public and private health agencies
and institutions working together to develop and
implement cost-effective risk-reduction programs.
Fortunately, such interventions may be currently
available. For example, the US Environmental
Protection Agency developed and implemented a
SunWise school-based program designed to teach
children how to protect themselves from overexpo-
sure to sun.50 This program has been reported to be
cost-effective with a return on investment of $2 to $4
saved in medical care costs and productivity lossesfor every dollar invested and could prevent more
than 50 premature deaths associated with melanoma
by 2015.50 This and other prevention programs that
might include changes in personal behaviors and
government policies designed to reduce exposure to
artificial sunlight, such as the use of indoor tanning
beds, may help in reducing the mortality burden
associated with melanoma.
Limitations
This study has some limitations. First, in estimat-
ing YPLL as a result of melanoma mortality, we used
life table data on all race/ethnicity as a proxy for life
expectancy of non-Hispanic other. This approach
may have introduced some uncertainty in our esti-
mates. Second, we used the HCA to estimate PVFLE.
This approach assumes that an individual produces a
stream of earnings that is valued only through
employment. Therefore, it fails to recognize the costs
of intangibles, which includes pain and suffering, the
psychosocial consequences of cancer disease, and
reductions in the quality of life.13 Third, our analysis
excludes morbidity costs associated with melanoma,
which includes the productivity loss from individuals
with melanoma before they die, costs of medical
treatment, nonmedical costs (eg, those associated
with time spent seeking cancer treatment and care),
and productivity losses for caregivers. These costs
represent a substantial amount of resources lost or
spent because of melanoma.
CONCLUSIONS
Despite these limitations, the health burden mea-
sured by YPLL and economic cost estimates pre-
sented in this article provide evidence of significant
numbers of premature deaths and substantial mor-
tality costs associated with cutaneous melanoma
during an individual’s lifetime. Given the increasing
incidence rate and mortality associated with mela-
noma in an era of declining mortality among other
major cancers, it appears that current prevention
efforts may not be adequate. Hence, it has been
suggested that perhaps new prevention strategies
that involve a multifaceted approach should be
adopted.51 This approach would include social mar-
keting, policy change, education, and sustained
intervention programs that may be required to mea-
surably shift knowledge, attitudes, and behaviors of
the population.51
In the past, estimates of health burden and eco-
nomic costs of diseases including cancer have
proven useful to guide health care policy debates
in the population.21,52 We hope that the information
reported in this article would be helpful in mobiliz-
ing interests and guiding resources to enable public
J AM ACAD DERMATOL
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S133.e10 Ekwueme et alhealth decision makers to develop the right health
policy and comprehensive intervention programs to
decrease the burden of melanoma mortality in the
United States.
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APPENDIX 1: GLOSSARY OF TECHNICAL
TERMS USED IN ARTICLE
Years of potential life lost (YPLL): The ex-
pected years of potential life lost because of a
particular disease during an individual’s lifetime. It
is part of the descriptive epidemiology that provides
information on the overall burden of a disease in the
population. Calculating YPLL provides an indication
of the impact of premature death from a particular
illness or injury on society. The information from
YPLL can be useful in establishing public health
priorities and policies.
Average years of life lost: This is the total YPLL
associated with a particular disease or injury in the
population for a given year divided by the number of
deaths from an illness or injury in the population in
that year.
YPLL rate: It is a rate used to compare the
estimated number of YPLL for two populations of
different sizes (eg, white and black). It is usuallyexpressed as per 100,000. It is calculated as: total
YPLL in a given year divided by the population and
then multiplied by 100,000.
Age-adjusted YPLL rate: It is a rate used to
compare the estimated number of YPLL between two
or more different populations (eg, racial/ethnic
groups) to eliminate the effects of different age
structures among these different populations. It is
calculated by the direct method, using the 2000 US
standard population. Like the crude rate, it is also
expressed as per 100,000.
Incidence-based cost: The lifetime costs result-
ing from new cases of an illness or injury that
occurred during a specified time period. It is one of
the methods used to calculate indirect (productivity)
costs of an illness or injury.
Prevalence-based cost: The total costs associ-
ated with existing cases of an illness or injury that
occurred in a specific time period divided by the total
population. It is another method used to calculate
indirect (productivity) costs of an illness or injury.
Human capital approach (HCA):Used to assess
the indirect costs or productivity losses from an
illness or injury as measured by forgone earnings
as a result of morbidity or premature mortality.
Willingness to pay: A method of measuring the
value an individual places on a good, service, or
reduction in the risk of death from an illness or injury
by estimating the maximum dollar an individual
would pay to obtain the good, service, or risk
reduction.
Present value of future lifetime earnings
(PVFLE): The discounted value of future lifetime
earnings lost as a result of premature death from an
illness or injury.
Productivity loss:Measure of resources forgone
to participate in an intervention, to seek care for a
health condition, for care giving, and as a result of
morbidity or premature mortality.
Discount rate:Used to convert future dollars and
future health outcomes to their present value.APPENDIX 2: THE RELATIVE
CONTRIBUTIONS OF EACH OF FOUR
MAJOR CANCER SITES TO MORTALITY
AND YPLL
We estimated the ratio of the relative contributions
of each of the 4major cancer sites (ie, breast, prostate,
colorectal, and lung), melanoma, and all malignant
cancers to years of potential life lost (YPLL) and
mortality in the population. We used all malignant
cancers as reference. The numerator of the ratio was
the YPLL for each cancer site divided by the YPLL for
allmalignant cancers and expressed as a percent. The
Fig 2. Years of potential life lost and mortality ratios for 4
major cancer sites, melanoma, and all malignant cancerse
United States, 2000 to 2006.
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S133.e12 Ekwueme et aldenominator was the number of deaths caused by
each cancer site divided by the number of deaths
caused by all malignant cancers and expressed as a
percent (ie, % YPLL/% mortality). The 45-degree line
(y = x) represents the line of equality, which indicates
a cancer site’s equal relative contribution to YPLL and
mortality. A cancer site with a ratio less than 1 indi-
cates that cancer contributes more to mortality than
to the number of YPLL. On the other hand, a ratio
greater than 1 indicates that cancer contributes more
to YPLL than to the number of deaths.
Fig 2 shows that melanoma and breast cancer
contributed more to YPLL than to mortality with
ratios of 1.23 and 1.22, respectively. On the other
hand, prostate cancer contributed more to mortality
than to YPLL with a ratio of 0.59.
